UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000027492
Receipt number R000030941
Scientific Title Studies on changes in serum butyrylcholinesterase activity of rivastigmine transdermal preparation in Alzheimer's type dementia patients and its effect on cognitive function, lipid / blood pressure / sugar metabolism
Date of disclosure of the study information 2017/05/25
Last modified on 2019/03/29 11:50:04

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Studies on changes in serum butyrylcholinesterase activity of rivastigmine transdermal preparation in Alzheimer's type dementia patients and its effect on cognitive function, lipid / blood pressure / sugar metabolism

Acronym

Study on serum butyrylcholinesterase activity of rivastigmine transdermal preparation in patients with Alzheimer type dementia

Scientific Title

Studies on changes in serum butyrylcholinesterase activity of rivastigmine transdermal preparation in Alzheimer's type dementia patients and its effect on cognitive function, lipid / blood pressure / sugar metabolism

Scientific Title:Acronym

Study on serum butyrylcholinesterase activity of rivastigmine transdermal preparation in patients with Alzheimer type dementia

Region

Japan


Condition

Condition

Altzheimer's disease

Classification by specialty

Neurology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Measurement of serum BuChE and an influential presence to a recognition function change, fat matter, low blood and sugar metabolism of an Alzheimer-type recognition shou patient before and after rivastigmine transdermal preparation are considered.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

Change in serum BuChE activity, change in cognitive function severity evaluation (MMSE, ADAS-J) at registration, 3 months after administration, 6 months after administration

Key secondary outcomes

TG, LDL, HDL, HbA1c, GOT, GPT, pancreatic amylase, MRI (VSRAD), blood pressure, pulsatility at the time of registration, 3 months after administration, 6 months after administration


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification

YES

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

YES

Concealment

No need to know


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Rivastigmine group: Rivastatch patch 9 mg, Rivasutatch patch 18 mg
Among the dosage and dose stated in the package insert, administration starts from 9 mg once a day, in principle, it increases to 18 mg once a day after 4 weeks.

Interventions/Control_2

Donepezil hydrochloride group: Regardless of the dosage form, it should be 10 mg or less.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients with mild and moderate Alzheimer's type dementia with complications of either hyperlipidemia, hypertension, or diabetes.

Key exclusion criteria

Patients with history of hypersensitivity to rivastigmine, components of donepezil hydrochloride or carbamate derivatives

Target sample size

140


Research contact person

Name of lead principal investigator

1st name Kudoh
Middle name
Last name Chiaki

Organization

Medical Corporation Kudoh Chiaki Neurosurgery Clinic

Division name

Neurosurgery

Zip code

143-0016

Address

1-23-10 Omoriokita, Ota-ku, Tokyo 143-0016

TEL

03-5767-0226

Email

kudouchiaki@yahoo.co.jp


Public contact

Name of contact person

1st name Kudoh
Middle name
Last name Chiaki

Organization

Medical Corporation Kudoh Chiaki Neurosurgery Clinic

Division name

Neurosurgery

Zip code

143-0016

Address

1-23-10 Omoriokita, Ota-ku, Tokyo 143-0016

TEL

03-5767-0226

Homepage URL


Email

kudouchiaki@yahoo.co.jp


Sponsor or person

Institute

Medical Corporation Kudoh Chiaki Neurosurgery Clinic

Institute

Department

Personal name



Funding Source

Organization

ONO PHARMACEUTICAL CO., LTD.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Mizuo Clinic Ethics Review Committee

Address

Wisteria-kan1F,3-9-1,Nakataminami,Izumi-ku,Yokohama-shi,Kanagawa,Japan

Tel

03-5413-8929

Email

info@mizuo-irb.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

医療法人社団くどうちあき脳神経外科クリニック(東京都)/Medical Corporation Kudoh Chiaki Neurosurgery Clinic(Tokyo)


Other administrative information

Date of disclosure of the study information

2017 Year 05 Month 25 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

31

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2017 Year 02 Month 02 Day

Date of IRB

2017 Year 02 Month 28 Day

Anticipated trial start date

2017 Year 06 Month 01 Day

Last follow-up date

2019 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded

2019 Year 12 Month 31 Day


Other

Other related information



Management information

Registered date

2017 Year 05 Month 25 Day

Last modified on

2019 Year 03 Month 29 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000030941


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name